ArticleAntimicrobial agents and chemotherapy2007
Improved assessment of plasmodium vivax response to antimalarial drugs by a colorimetric double-site plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 33 citations in OpenAlex.
- Monitoring the Efficacy of Chloroquine-Primaquine Therapy for Uncomplicated Plasmodium vivax Malaria in the Main Transmission Hot Spot of Brazil.Antimicrobial agents and chemotherapy · 2019Trial
- Article
- Influence ofAntimicrobial agents and chemotherapy · 2020Article
- Measuring ex vivo drug susceptibility in Plasmodium vivax isolates from Cambodia.Malaria journal · 2017Article
- Genome-wide diversity and differentiation in New World populations of the human malaria parasite Plasmodium vivax.PLoS neglected tropical diseases · 2017Article
- Diagnosis and Treatment of Plasmodium vivax Malaria.The American journal of tropical medicine and hygiene · 2016Article
- Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry.Malaria journal · 2015Article
- Parasite biomass-related inflammation, endothelial activation, microvascular dysfunction and disease severity in vivax malaria.PLoS pathogens · 2015Article
- In vitro susceptibility of Plasmodium vivax to antimalarials in Colombia.Antimicrobial agents and chemotherapy · 2014Article
- Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India.Malaria journal · 2014Article
- Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.Malaria journal · 2014Article
- Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity.Antimicrobial agents and chemotherapy · 2013Article
- Use of a colorimetric (DELI) test for the evaluation of chemoresistance of Plasmodium falciparum and Plasmodium vivax to commonly used anti-plasmodial drugs in the Brazilian Amazon.Malaria journal · 2013Article
- In vitro chloroquine resistance for Plasmodium vivax isolates from the Western Brazilian Amazon.Malaria journal · 2013Article
- Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.Trends in parasitology · 2012Review
- Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine.Malaria journal · 2011Article
- The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.Antimicrobial agents and chemotherapy · 2011Article
- In vitro activity of pyronaridine against multidrug-resistant Plasmodium falciparum and Plasmodium vivax.Antimicrobial agents and chemotherapy · 2010Article
- Plasmodium vivax susceptibility to ferroquine.Antimicrobial agents and chemotherapy · 2010Article
- Resistance to therapies for infection by Plasmodium vivax.Clinical microbiology reviews · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of Plasmodium vivax resistance to chloroquine has been reported in several countries of Asia and South America. However, the resistance of P. vivax is insufficiently documented for three reasons: it has received far less attention than P. falciparum; in vivo investigations are handicapped by the existence of hypnozoites, which make it difficult to distinguish between recrudescences due to drug failure and relapses due to dormant forms in the liver; and in vitro studies are greatly limited by the poor growth of P. vivax. We report on the adaptation to P. vivax of a colorimetric double-site Plasmodium lactate dehydrogenase antigen capture enzyme-linked immunosorbent assay previously developed for P. falciparum. The assay proved remarkably sensitive, as under optimal conditions it could detect P. vivax parasitemia levels as low as 10(-8). The technique, which relies on the detection of protein synthesis by the parasite, yielded steep drug-response curves, leading to the precise determination of the 50% inhibitory concentrations for a high proportion of isolates. Chloroquine-resistant parasites were identified in an area where this phenomenon had been documented by in vivo methods. Thus, the results indicate that the in vitro susceptibility of P. vivax can now be monitored easily and efficiently. The data suggest that the threshold of resistance is similar to that of P. falciparum, i.e., in the range of 100 nM for chloroquine and 15 nM for pyronaridine. However, further studies are required to precisely define the cutoff for resistance and the sensitivity to each drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.